glpg1972
Small moleculeexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2015 (NCT02612246)
Timeline
Indications
Mechanism of action
- ADAMTS5INHIBITOR
ADAMTS5 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- glpg1972
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04137341 | Phase 1 | Oct 9, 2019 | Galapagos NV |
| NCT04136327 | Phase 1 | Sep 13, 2019 | Galapagos NV |
| NCT03595618 | Phase 2 | Aug 14, 2018 | Galapagos NV, Servier |
| NCT03311009 | Phase 1 | May 15, 2017 | Galapagos NV |
| NCT03143725 | Phase 1 | Apr 14, 2017 | Galapagos NV |
| NCT02851485 | Phase 1 | Jul 1, 2016 | Galapagos NV, Pharmaceutical Research Associates, Inc. (PRA) |
| NCT02612246 | Phase 1 | Nov 1, 2015 | Galapagos NV |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Galapagos NV | For profit | 7 | 7 | 2 | 2015 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 1 | 0 | 1 | 2016 |
| Servier | For profit | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1